Zyflamend Cancer Research Results

ZYF, Zyflamend: Click to Expand ⟱
Features:

Zyflamend — is a proprietary, oral, multi-herbal botanical formulation manufactured by New Chapter, containing concentrated extracts of ten plants: rosemary, turmeric, ginger, holy basil, green tea, Hu Zhang (Polygonum cuspidatum), Chinese goldthread, barberry, oregano, and Baikal skullcap. Classified as a multi-component botanical protocol and dietary supplement, Zyflamend (ZYF) combines anti-inflammatory and polyphenolic phytochemicals including curcuminoids, catechins, carnosic acid derivatives, berberine-related alkaloids, resveratrol-related constituents, and baicalin-related flavonoids. Its anticancer activity has been investigated primarily in prostate cancer models, including castration-resistant prostate cancer, with additional studies in melanoma and pancreatic neuroendocrine tumor cells. It is not an approved cancer therapy.

Zyflamend – Ingredients and Quantities

Serving size: 2 capsules daily.

Total botanical extracts: 780 mg.

Rank Ingredient Botanical Name Quantity Extract Type Major Bioactive Compounds
1 Rosemary Salvia rosmarinus 150 mg 100 mg supercritical + 50 mg hydroethanolic Carnosic acid, carnosol, rosmarinic acid
2 Turmeric Curcuma longa 110 mg 100 mg aqueous + 10 mg supercritical Curcumin, turmerones
3 Ginger Zingiber officinale 100 mg 54 mg supercritical + 46 mg aqueous Gingerols, shogaols, zingiberene
4 Holy Basil (Tulsi) Ocimum tenuiflorum 100 mg Hydroethanolic Ursolic acid, eugenol, rosmarinic acid
5 Green Tea Camellia sinensis 100 mg Aqueous EGCG, catechins, polyphenols
6 Hu Zhang Reynoutria japonica (Polygonum cuspidatum) 80 mg Hydroethanolic Resveratrol, polydatin, emodin
7 Chinese Goldthread Coptis chinensis 40 mg Aqueous Berberine, coptisine, palmatine
8 Barberry Berberis vulgaris 40 mg Hydroethanolic Berberine, berbamine
9 Oregano Origanum vulgare 40 mg Supercritical Carvacrol, thymol
10 Chinese Skullcap Scutellaria baicalensis 20 mg Aqueous Baicalin, baicalein, wogonin
Total Botanical Extracts 780 mg Per 2 capsules

Other ingredients: Extra-virgin olive oil, hypromellose capsule, candelilla wax and organic yellow beeswax. Quantities not disclosed.

Notes: Botanical extract quantities are not equivalent to purified active-compound quantities. The concentrations of curcumin, EGCG, resveratrol, berberine and other individual phytochemicals are not specified. Values reflect the previously listed formulation and should be checked against the product label for the specific batch.

Primary mechanisms (ranked):

  1. Androgen receptor signaling inhibition: ↓ AR expression and transcriptional activity, with ↓ PSA and attenuation of IGF-1R/AKT-associated survival signaling in prostate cancer models.
  2. Epigenetic regulation: ↓ class I and II histone deacetylases (HDACs), ↑ CBP/p300 and histone H3 acetylation, and ↑ p21/CDKN1A expression, promoting cell-cycle arrest.
  3. Inflammatory pathway suppression: ↓ COX-1 and COX-2 enzymatic activity, with context-dependent ↓ NF-κB signaling and inflammatory mediators.
  4. Apoptosis induction: ↑ caspase-3 activation and PARP cleavage, contributing to decreased tumor cell survival.
  5. Cell-cycle regulation: ↑ p21 and p27, reduced proliferation and context-dependent cell-cycle arrest.
  6. ER stress and autophagy signaling: ↑ PERK, IRE1α, eIF2α, CHOP and JNK activation, promoting autophagy-associated apoptosis in pancreatic neuroendocrine tumor models.
  7. Growth and survival signaling suppression: ↓ phosphorylated AKT, STAT3 and PKC in selected prostate cancer models.
  8. Hormonal therapy sensitization: enhanced bicalutamide-associated growth inhibition in vitro and enhanced androgen-deprivation effects in prostate cancer xenografts.

Bioavailability / PK relevance: Zyflamend is administered orally as an oil-based mixture of botanical extracts. Its constituents have markedly different absorption, metabolism, conjugation, tissue distribution and elimination characteristics. Some polyphenols undergo extensive intestinal and hepatic first-pass metabolism. No validated integrated human plasma concentration profile or pharmacokinetic exposure-response relationship exists for the complete formulation. The manufacturer recommends two capsules daily with food; this is a supplement dose, not an established anticancer dose.

In-vitro vs systemic exposure relevance: Many mechanistic studies used approximately 200 µg/mL of complete Zyflamend preparation, often over 24–96 hours. Whether equivalent concentrations of the intact formulation or relevant active constituents can be achieved in human tumor tissue is unknown and has not been demonstrated. Oral absorption produces individual metabolites rather than a circulating mixture identical to the culture preparation. Consequently, direct translation of these in-vitro effects to standard oral dosing is not established.

Clinical evidence status: Preclinical: multiple prostate cancer cell studies and animal xenograft experiments demonstrate antiproliferative effects. Small human: an uncontrolled Phase I study in 23 evaluable men with high-grade prostatic intraepithelial neoplasia investigated an intervention including Zyflamend and other supplements over 18 months, reporting generally mild adverse effects, reduced NF-κB staining, and PSA changes in some participants. RCT: no adequately powered randomized evidence establishes anticancer efficacy. Adjunct use: experimental only; not established as a replacement for or proven enhancement of conventional cancer therapy.

Safety / limitations: Reported clinical adverse effects were mainly mild gastrointestinal symptoms. Potential concerns include herb-drug interactions, effects on platelet function, altered drug-metabolizing enzymes and transporters, and rare hepatic adverse effects associated with certain concentrated botanical extracts. Caution is warranted with anticoagulants, antiplatelet medications, anticancer drugs, liver disease, and perioperative use. In-vitro inhibition of nonmalignant prostate epithelial cell proliferation indicates that tumor selectivity cannot be assumed.

Zyflamend: Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Androgen Receptor / PSA ↓ AR expression and activity; ↓ PSA Not established G Reduced androgen-dependent tumor signaling Core mechanism in prostate cancer, including castration-resistant models. May affect AR expression and associated survival signaling.
2 HDAC1–7 / Histone H3 Acetylation ↓ HDAC expression and activity; ↑ histone H3 acetylation Not fully characterized G Epigenetic suppression of proliferation Strong mechanistic evidence in CWR22Rv1 cells. Goldthread and Baikal skullcap contributed substantially to HDAC modulation.
3 p21 / p27 / Cell Cycle ↑ p21; ↑ p27; ↓ proliferation ↓ proliferation observed G Cell-cycle arrest and growth suppression p21 knockdown partially reverses growth inhibition, supporting a functional role. Effects are not exclusive to cancer cells.
4 COX-1 / COX-2 / Prostaglandins ↓ COX enzymatic activity ↓ COX activity possible P–G Anti-inflammatory signaling Direct COX inhibition demonstrated. Cancer-cell apoptosis can occur independently of COX-2 expression.
5 NF-κB / Inflammatory Signaling ↓ NF-κB (context-dependent) Not established G Reduced inflammatory and survival signaling Reduced tissue NF-κB immunostaining reported in the small HGPIN clinical study; clinical consequences remain uncertain.
6 Caspase-3 / PARP / Apoptosis ↑ caspase-3; ↑ PARP cleavage; ↑ apoptosis Selectivity uncertain G Programmed tumor-cell death Observed in prostate cancer models. Apoptotic induction is cell-type and concentration-dependent.
7 IGF-1R / PI3K / AKT ↓ pAKT and associated survival signaling Not established G Reduced proliferative and castration-resistant signaling Supported by prostate cancer models and tumor xenograft biomarker measurements.
8 STAT3 / PKC ↓ pSTAT3; ↓ activated PKC Not established G Suppression of oncogenic signaling Observed in LNCaP prostate cancer cells; broader relevance remains model-dependent.
9 ER Stress / PERK / IRE1α / CHOP ↑ ER stress and CHOP signaling Not established G Stress-mediated apoptosis Demonstrated primarily in pancreatic β-TC6 insulinoma cells at high experimental concentrations.
10 JNK / Autophagy / Apoptosis ↑ JNK; ↑ autophagy-associated apoptosis Not established G Stress-induced tumor-cell death JNK inhibition reduced apoptosis in pancreatic neuroendocrine tumor cells. Autophagy effects vary by cancer model.
11 ERK1/2 / CBP-p300 ↑ pERK; ↑ CBP/p300 acetylation Not established G p21 transcriptional regulation ERK activation supports p21 induction in CWR22Rv1 cells; represents a context-dependent growth-inhibitory response.
12 Hormonal Therapy Sensitization ↑ response to bicalutamide and androgen deprivation Not established G Potential endocrine therapy adjunct In-vitro combination studies and mouse xenografts suggest benefit; no clinical efficacy established.
13 Chemosensitization ↑ stress-associated apoptosis with selected agents Not established G Experimental combination activity Effects with doxorubicin and streptozotocin were investigated in pancreatic cell models. Human benefit is unproven.
14 ROS / Oxidative Stress ↔ (context-dependent) ↔ (context-dependent) R–G Secondary redox modulation Contains antioxidant phytochemicals, but a consistent ROS-directed anticancer mechanism has not been established for the complete preparation.
15 Clinical Translation Constraint Effective tissue exposure unverified Normal-cell growth effects observed in vitro G Uncertain clinical anticancer efficacy Mixed-extract PK remains undefined. Many experiments use 200 µg/mL preparation. Small uncontrolled human study, formulation complexity and uncertain drug interactions limit extrapolation.

TSF: P: 0–30 min   R: 30 min–3 hr   G: >3 hr



Scientific Papers found: Click to Expand⟱
9123- ZYF,    Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial
- Trial, Pca, NA
PSA↓, CRP↓, NF-kB↓, toxicity↓,
9124- ZYF,    Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer
- in-vitro, Pca, NA
AntiCan↑, TumCG↓, eff↑, p‑Akt↓, PSA↓, HDAC↓, AR↓,
9125- ZYF,    Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells
- in-vitro, Pca, NA
HDAC↓, Ingr↝, CBP↑, TumCP↓, P21↑, Ingr↝,
9126- ZYF,  Bical,    Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
AR↓, NKX3.1↓, PSA↓, Synergy↑,
9127- ZYF,    Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer
- in-vitro, Pca, 22Rv1
AR↓, IGF-1R↓, TumCP?, PI3K↓, p‑Akt↓,
9128- ZYF,    Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression
- in-vitro, Pca, LNCaP
COX1?, COX2/PTGS2?, P21↑, TumCG↓, cl‑PARP↑, Casp3↑, Apoptosis↑, AR↓, STAT3↓, p‑PKCδ↓,
9129- ZYF,    Zyflamend-mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb protein phosphorylation
- in-vitro, Pca, PC3
Inflam↓, COX1↓, COX2/PTGS2↓, 5LO↓, 5-HETE↓, TumCP↓, TumCCA↑, Apoptosis↑, 12LOX↓, p‑P21↑, pRB↓,
9130- ZYF,    Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of NF-kappa B activation and NF-kappa B-regulated gene products
- in-vitro, Var, NA
NF-kB↓, Synergy↑, angioG↓, VEGF↓, COX2/PTGS2↓, MMP9↓, TumCI↓,
9131- ZYF,    Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets
- vitro+vivo, PC, NA
TumCP↓, ChemoSen↑, Apoptosis↑, NF-kB↓, cycD1/CCND1↓, cMyc↓, COX2/PTGS2↓, Bcl-2↓, IAP1↓, VEGF↓, survivin↓, ICAM-1↓, CXCR4↓, TumCG↓, Ki-67↓, MMP9↓,
9132- ZYF,    Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells
- in-vitro, Melanoma, NA
TumCP↓, TumCI↓, angioG↓, TumMeta↓, Inflam↓, TumCG↓, Apoptosis↑,
9133- ZYF,    Zyflamend induces apoptosis in pancreatic cancer cells via modulation of the JNK pathway
- in-vitro, PC, NA
TumCP↓, Apoptosis↑, TumCCA↑, ER Stress↑, TumAuto↑, JNK↑, Synergy↑, cl‑Casp3↑, cl‑PARP↑, p‑Akt↓, ERK↓, PERK↑, eIF2α↑, p‑IRE1↑, CHOP/DDIT3↑, AMPK↑,

Showing Research Papers: 1 to 11 of 11

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   5-HETE↓, 1,   5LO↓, 1,   AMPK↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 5,   Bcl-2↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   IAP1↓, 1,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↓, 3,   ERK↓, 1,   IGF-1R↓, 1,   JNK↑, 1,   PI3K↓, 1,   p‑PKCδ↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

CBP↑, 1,   cMyc↓, 1,   HDAC↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↑, 1,   ER Stress↑, 1,   p‑IRE1↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

NKX3.1↓, 1,   cl‑PARP↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   Ki-67↓, 1,   P21↑, 2,   p‑P21↑, 1,   pRB↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 1,   TumCG↓, 4,   TumCP?, 1,   TumCP↓, 5,  

Migration(tgid=13) ⓘ

MMP9↓, 2,   TumCI↓, 2,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   VEGF↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1?, 1,   COX1↓, 1,   COX2/PTGS2?, 1,   COX2/PTGS2↓, 3,   CXCR4↓, 1,   ICAM-1↓, 1,   Inflam↓, 2,   NF-kB↓, 3,   PSA↓, 3,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 4,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   eff↑, 1,   Synergy↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 4,   CRP↓, 1,   PSA↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   toxicity↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,  
Total Targets: 62

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:515  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page